76
|
Süsskind S, Roth J. A Note on the Treatment of Two Cases of Infantile Leishmaniasis with Stilbamidine. ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY 2016. [DOI: 10.1080/00034983.1943.11685177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
77
|
Růžička F, Bezdíček O, Roth J, Sieger T, Vymazal J, Růžička E, Mueller K, Jech R. ID 328 – Anxiety-related increase of functional connectivity in the ventromedial prefrontal network in Parkinson’s disease. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
78
|
Gescheidt T, Majerová V, Menšíková K, Dušek L, Czekóová K, Kotková P, Kaňovský P, Roth J, Bareš M. ID 16 – Impulse control disorders in young-onset patients with Parkinson’s disease: Cross-sectional study seeking associated factors with regard of personal characteristics. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
79
|
Fröhling M, Vogl T, Loser K, Paruzel P, Blackshear PJ, Stumpo DJ, Roth J, Pap T, Stratis A. A1.30 A key role of S100A9 in the pathogenesis of psoriatic arthritis in TTP/S100 deficient mice. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.30] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
80
|
de Munter W, Geven EJW, Blom AB, Walgreen B, Helsen MMA, Joosten LAB, Roth J, Vogl T, van de Loo FAJ, Koenders MI, van den Berg WB, van der Kraan PM, van Lent PLEM. A1.14 Synovial macrophages promote TGF-β signalling but protect against influx of S100A8/S100A9-producing cells after intra-articular injections of oxidised low-density lipoproteins. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
81
|
Geven EJW, Abdollahi-Roodsaz S, Sloetjes A, Koenders MI, Foell D, Roth J, Vogl T, van Lent PLEM. A1.09 S100-damps in IL-1RA -/-mice, a serum biomarker and in vivoimaging tool to assess joint inflammation and destruction in experimental seronegative arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-209124.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
82
|
Kloos C, Müller N, Hartmann P, Lehmann T, Sämann A, Roth J, Wolf G, Müller UA. High Quality of Diabetes Care Based Upon Individualised Treatment Goals - A Cross Sectional Study in 4784 Patients in Germany. Exp Clin Endocrinol Diabetes 2016; 124:294-9. [PMID: 26824283 DOI: 10.1055/s-0035-1569380] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE Recent guidelines recommend an individualized approach towards patients with diabetes mellitus. Data of a programme dealing with quality of diabetes care, "Diabetes TÜV" of the Deutsche BKK was reappraised in the light of recent evidence applying these recommendations. PATIENTS AND METHODS Data originates from a population-based study in primary diabetes care in Germany. Patients with diabetes mellitus insured by the Deutsche BKK were invited to participate. From 2000 to 2004 data of 4 784 patients participated. Double or multiple visits were not included. HbA1c was analysed in 0.5% categories and in age groups below and above 70 years. HbA1c was DCCT adjusted. RESULTS A total of 368 patients with diabetes mellitus type 1 (DM1) (42% women, HbA1c 54 mmol/mol (7.1%), BP 136/79 mmHg) and 4 416 patients with diabetes type 2 (DM2) (44% women, HbA1c 48.6 mmol/mol (6.6%), BP 142/81 mmHg) were included.). An HbA1c of 53 mmol/mol (7%) or less was found in 70%, less than 64 mmol/mol (8%) in 87% of all patients, and higher than 86 mmol/mol (10%) in 2.8%. The detailed analysis shows that an HbA1c of <=47.6 mmol/mol (6.5%) is achieved of 38% of people with DM1 and 56% with DM2, an HbA1c <=66 mmol/mol (8.0%) of 79% and 88%, respectively.The mean systolic blood pressure (BP) was 142 mmHg, the diastolic BP was 81 mmHg. Systolic BP increased with age (systolic BP: < 50 years 131 mmHg; 50-70 years 142 mmHg; > 70 years 144 mmHg/diastolic BP: < 50 years 81 mmHg; 50-70 years 82 mmHg; > 70 years 80 mmHg). Using WHO grading, BP is mainly mildly elevated (grade 1: 41% (n=1942); grade 2, 17% (n=820) grade 3 6% (n=281). In 10 patients (0.2%) HbA1c above 86 mmol/mol (10.0%) coincides with a BP WHO grade 3. CONCLUSIONS In recent years new evidence is available regarding treatment targets. The reappraisal of a cross sectional study of a quality assurance programme of a German health insurance in a differentiated way demonstrates that more than 2/3 of the people with diabetes mellitus meet their specific goals. Only very few patients are at imminent risk due to bad glycaemic control and high blood pressure. Old patients may be at risk of overtreatment. Strategies aiming at adapting pharmacological interventions in older patients must be conceived.
Collapse
|
83
|
Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, Drennan MB, Lavric M, Foell D, Cuvelier CA, De Vos M, Delanghe J, Van den Bosch F, Elewaut D. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 2015; 75:1357-62. [PMID: 26698844 PMCID: PMC4941173 DOI: 10.1136/annrheumdis-2015-208025] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Accepted: 11/27/2015] [Indexed: 12/18/2022]
Abstract
INTRODUCTION Microscopic bowel inflammation is present in up to 50% of patients with spondyloarthritis (SpA) and is associated with more severe disease. Currently no reliable biomarkers exist to identify patients at risk. Calprotectin is a sensitive marker of neutrophilic inflammation, measurable in serum and stool. OBJECTIVES To assess whether serum and faecal calprotectin in addition to C-reactive protein (CRP) can be used to identify patients with SpA at risk of microscopic bowel inflammation. METHODS Serum calprotectin and CRP were measured in 125 patients with SpA. In 44 of these patients, faecal samples were available for calprotectin measurement. All 125 patients underwent an ileocolonoscopy to assess the presence of microscopic bowel inflammation. RESULTS Microscopic bowel inflammation was present in 53 (42.4%) patients with SpA. Elevated serum calprotectin and CRP were independently associated with microscopic bowel inflammation. Faecal calprotectin was also significantly higher in patients with microscopic bowel inflammation. Patients with CRP and serum calprotectin elevated had a frequency of bowel inflammation of 64% vs 25% in patients with low levels of both. When either CRP or serum calprotectin was elevated, the risk was intermediate (40%) and measuring faecal calprotectin provided further differentiation. Hence we suggest a screening approach where initially serum calprotectin and CRP are assessed and, if necessary, faecal calprotectin. The model using this scenario provided an area under the ROC curve of 74.4% for detection of bowel inflammation. CONCLUSIONS Calprotectin measurements in stool and serum, in addition to CRP, may provide a promising strategy to identify patients with SpA at risk of bowel inflammation and could play a role in overall patient stratification.
Collapse
|
84
|
Kerner W, Freckmann G, Müller U, Roth J, Schleicher E, Niederau C, Müller-Wieland D, Landgraf R, Heinemann L. Positionspapier der Kommission für Labordiagnostik in der Diabetologie der DGKL und der DDG. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0041-109081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
85
|
Simm B, Ott D, Pollatzek E, Murgott J, Gerstberger R, Rummel C, Roth J. Effects of prostaglandin E2 on cells cultured from the rat organum vasculosum laminae terminalis and median preoptic nucleus. Neuroscience 2015; 313:23-35. [PMID: 26608124 DOI: 10.1016/j.neuroscience.2015.11.034] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 10/30/2015] [Accepted: 11/16/2015] [Indexed: 02/09/2023]
Abstract
The time course of the induction of enzymes responsible for the formation of prostaglandin E2 (PGE2) after an inflammatory insult, in relation to the concomitant febrile response, suggests that peripherally generated PGE2 is involved in the induction of the early phase of fever, while centrally produced PGE2 exerts pyrogenic capacities during the later stages of fever within the hypothalamic median preoptic nucleus (MnPO). The actions of peripherally derived PGE2 on the brain might occur at the level of the organum vasculosum laminae terminalis (OVLT), which lacks a tight blood-brain barrier and is implicated in fever, while the effects of PGE2 within the MnPO might interfere with glutamatergic neurotransmission within a recently characterized central efferent pathway for the activation of cold-defence reactions. Using the fura-2 ratio imaging technique we, therefore, measured changes of the intracellular Ca(2+)-concentration in primary neuroglial microcultures of rat OVLT and MnPO stimulated with PGE2 and/or glutamate. In cultures from the OVLT, as opposed to those derived from the MnPO, substantial numbers of neurons (8% of 385), astrocytes (19% of 645) and microglial cells (28% of 43) directly responded to PGE2 with a transient increase of intracellular Ca(2+). The most pronounced effect of PGE2 on cells from MnPO microcultures was its modulatory influence on the strength of glutamate-induced Ca(2+)-signals. In 72 out of 512 neurons and in 105 out of 715 astrocytes PGE2 significantly augmented glutamate-induced Ca(2+)-signals. About 30% of these neurons were GABAergic. These observations are in agreement with putative roles of peripheral PGE2 as a directly acting circulating agent at the level of the OVLT, and of central MnPO-intrinsic PGE2 as an enhancer of glutamatergic neurotransmission, which causes disinhibition of thermogenic heat production, a crucial component for the manifestation of fever. In microcultures from both brain sites investigated incubation with PGE2 significantly reduced the lipopolysaccharide-induced release of cytokines (tumor necrosis factor-α and interleukin-6) into the supernatant. PGE2, thus, seems to be involved in a negative feed-back loop to limit the strength of the brain inflammatory process and to play a dual role with pro- as well as anti-inflammatory properties.
Collapse
|
86
|
Harden LM, Kent S, Pittman QJ, Roth J. Fever and sickness behavior: Friend or foe? Brain Behav Immun 2015; 50:322-333. [PMID: 26187566 DOI: 10.1016/j.bbi.2015.07.012] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Revised: 07/10/2015] [Accepted: 07/13/2015] [Indexed: 12/21/2022] Open
Abstract
Fever has been recognized as an important symptom of disease since ancient times. For many years, fever was treated as a putative life-threatening phenomenon. More recently, it has been recognized as an important part of the body's defense mechanisms; indeed at times it has even been used as a therapeutic agent. The knowledge of the functional role of the central nervous system in the genesis of fever has greatly improved over the last decade. It is clear that the febrile process, which develops in the sick individual, is just one of many brain-controlled sickness symptoms. Not only will the sick individual appear "feverish" but they may also display a range of behavioral changes, such as anorexia, fatigue, loss of interest in usual daily activities, social withdrawal, listlessness or malaise, hyperalgesia, sleep disturbances and cognitive dysfunction, collectively termed "sickness behavior". In this review we consider the issue of whether fever and sickness behaviors are friend or foe during: a critical illness, the common cold or influenza, in pregnancy and in the newborn. Deciding whether these sickness responses are beneficial or harmful will very much shape our approach to the use of antipyretics during illness.
Collapse
|
87
|
Ruzicka F, Bezdicek O, Roth J, Sieger T, Vymazal J, Ruzicka E, Mueller K, Jech R. Anxiety and salivary cortisol changes in Parkinson's disease are related to global connectivity of the ventromedial prefrontal network. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
88
|
Jech R, Ruzicka F, Bezdicek O, Sieger T, Vymazal J, Ruzicka E, Mueller K, Roth J. Dysfunctional motor and cognitive networks in Parkinson's disease detected by resting state fMRI. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
89
|
Bares M, Gescheidt T, Ibarburu Lorenzo Y Losada V, Mensikova K, Dusek L, Czekoova K, Menclova P, Kanovsky P, Roth J. Impulse control disorders in young-onset patients with Parkinson’s disease: cross-sectional study seeking associated factors with regard of personal characteristics. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
90
|
Wilsmann-Theis D, Wagenpfeil J, Holzinger D, Roth J, Koch S, Schnautz S, Bieber T, Wenzel J. Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. J Eur Acad Dermatol Venereol 2015; 30:1165-70. [PMID: 26333514 DOI: 10.1111/jdv.13269] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2015] [Accepted: 05/21/2015] [Indexed: 12/01/2022]
Abstract
BACKGROUND Psoriasis is a chronic skin disease with deregulation of proteins in the immune system. These proteins include members of the heterogeneous S100 family, which have been discussed as potential biomarkers for disease severity. OBJECTIVE The aim of this study was to evaluate the impact of S100A7, S100A8, S100A9 and S100A12 as possible markers for disease activity in patients with psoriasis skin disease. PATIENTS AND METHODS S100A7, S100A8, S100A9 and S100A12 mRNA expression was determined in the skin of patients with psoriasis and controls (N = 341) by gene expression analyses. In addition, S100 serum levels were investigated by ELISA in an independent cohort of psoriasis patients (i) untreated, with different manifestations (skin/joints), (ii) under treatment (etanercept) and (iii) healthy controls, (N = 55). RESULTS All S100-subtypes included are significantly upregulated in psoriasis skin lesions when compared with atopic dermatitis, lichen ruber and healthy donors. In untreated psoriasis patients, S100A12-serum levels showed the closest association with disease activity (PASI) (r = 0.542; P < 0.01). Serum levels decreased under treatment with etanercept (P < 0.05). CONCLUSION Among the investigated S100-proteins, S100A12 showed the closest association with disease activity and therapeutic response and might therefore provide a valuable biomarker for psoriasis.
Collapse
|
91
|
Roth J, Milke B, Müller N, Zitterbart U, Rechtacek S, Rechtacek T, Kloos C, Wolf G, Müller UA. People with type 2 diabetes on premixed insulin therapy: how is the daily insulin dose partitioned and are there effects on the metabolic control? Exp Clin Endocrinol Diabetes 2015; 123:368-70. [PMID: 26077385 DOI: 10.1055/s-0035-1548796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
AIM To investigate the correctness of the recommendation for dose distribution in premixed insulin therapy, with two thirds of daily insulin dose before breakfast and one third of daily insulin dose before dinner. METHODS The individual insulin dose distribution and metabolic control of people with Type 2 diabetes treated with premixed insulin therapy were studied in a cross sectional study involving 199 patients in a university outpatient department and 2 general practices in 2010. RESULTS All 199 patients were treated with premixed human insulin. The mean pre-breakfast dose was 57% (min. 32%, max. 83%) and the mean pre-dinner dose 43% (17-67%) of the total daily insulin. A pre-breakfast dose of exactly two thirds of total daily insulin was used by 6.5% (n=13), about two thirds, i. e., 60-70%, was injected by 27.6% of the patients. The diurnal insulin distribution<60%, 60% up to 70% and > 70% pre-breakfast insulin did not make any difference in HbA1c, which was 7.3% (56 mmol/mol) each. CONCLUSION The quite common recommendation in German and Austrian medical textbooks, that premixed insulin therapy should consists of a dose distribution with two thirds before breakfast and one third before dinner, is not observed in daily practice. Diurnal insulin dose distribution and HbA1c are not associated in this cohort. Novelty statement: The circadian insulin dose distribution of 2/3 before breakfast and 1/3 before dinner could not be confirmed for patients with diabetes type 2 and conventional insulin therapy. No correlation between metabolic control and insulin circadian insulin dose distribution was detected.
Collapse
|
92
|
Popp D, Petersen B, Rühle F, Roth J. OP0192 S100 Proteins in Dendritic Cells Regulate Inflammatory Processes. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
93
|
Cypers H, Varkas G, Debusschere K, Vogl T, Roth J, Lavric M, Föll D, Cuvelier C, De Vos M, van den Bosch F, Elewaut D. SAT0248 Calgranulins are Elevated in Spondyloarthritis and Reflect the Presence of Acute Microscopic Bowel Inflammation. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
94
|
van den Bosch M, Blom A, Schelbergen R, Vogl T, Roth J, van den Berg W, van der Kraan P, van Lent P. OP0249 The Alarmins S100A8/A9 Induce Canonical WNT Signaling in Naïve Mouse Knee Joints and Experimental OA. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
95
|
Fassl S, Holzinger D, Vogl T, Gattorno M, Omenetti A, Chae J, Aksentijevich I, Austermann J, Roth J. OP0193 Pyrin and PSTPIP1, Mutated in FMF, PAPA-, and PAMI Syndrome, are Involved in the Hypersecretion of Alarmins MRP8/14. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
96
|
Gran S, Schäfers M, Roth J, Vogl T. FRI0606 In Vivo Imaging of Phagocyte Migration in Inflammatory Processes by Fluorescent Cell Tracking. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
97
|
de Munter W, Blom A, van der Kraan P, Roth J, Vogl T, van den Berg W, van Lent P. OP0152 Synovial Macrophages Promote TGF-β Signaling After Intra-Articular Injections of Oxidized LDL in Naïve Murine Knee Joints, Preventing Production of Pro-Inflammatory Factors S100A8/9, Chemokines and Aggrecanase-Induced Neo-Epitopes. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
98
|
de Munter W, van den Bosch M, Annet S, Croce K, Hogg N, Vogl T, Roth J, van den Berg W, van der Kraan P, van Lent P. SAT0006 High Systemic LDL Cholesterol Levels Lead to Synovial Activation and Strongly Accelerate Development of Ectopic Bone Formation During Experimental Osteoarthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
99
|
Thurainayagam S, Wixler V, Hermann S, Roth J, Vogl T. AB0143 Uncontrolled Expression of S100A8 Homodimers in the Absence of S100A9 Exacerbates TNFα-Mediated Psoriatic-Like Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
100
|
Zenker S, Kondapuram M, Roth J, Hermann S, Faust A, Schäfers M, Vogl T. OP0155 New Optical in Vivo Imaging of the Alarmin S100A9 in an Experimental Autoimmune Model of Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|